48104 Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices 

to provide additional information to 

HRSA by October 24, 2017, 12:00 p.m. 

Eastern Time. Please see contact 

information below. 

FOR FURTHER INFORMATION CONTACT: 

Anyone requesting information 

regarding the ACHDNC should contact 

Ann Ferrero, Maternal and Child Health 

Bureau (MCHB), HRSA, in one of three 

ways: (1) Send a request to the following 

address: Ann Ferrero, MCHB, HRSA 

5600 Fishers Lane, Room 18N100C, 

Rockville, MD 20857; (2) call 301–443– 

3999; or (3) send an email to: AFerrero@

hrsa.gov. 

SUPPLEMENTARY INFORMATION: The 

ACHDNC provides advice to the 

Secretary of HHS on the development of 

newborn screening activities, 

technologies, policies, guidelines, and 

programs for effectively reducing 

morbidity and mortality in newborns 

and children having, or at risk for, 

heritable disorders. In addition, 

ACHDNC’s recommendations regarding 

inclusion of additional conditions and 

inherited disorders for screening which 

have been adopted by the Secretary are 

then included in the Recommended 

Uniform Screening Panel (RUSP). 

Conditions listed on the RUSP 

constitute part of the comprehensive 

preventive health guidelines supported 

by HRSA for infants and children under 

section 2713 of the Public Health 

Service Act, codified at 42 U.S.C. 

300gg–13. Under this provision, nongrandfathered health plans are required 

to cover screenings included in the 

HRSA-supported comprehensive 

guidelines without charging a copayment, co-insurance, or deductible for 

plan years (i.e., policy years) beginning 

on or after the date that is one year from 

the Secretary’s adoption of the 

condition for screening. 

The meeting agenda will include: (1) 

An update on states’ progress toward 

the newborn screening timeliness goals 

outlined by the Committee; (2) a 

presentation on phase 2 of the spinal 

muscular atrophy evidence review; (3) 

presentations on newborn screening 

topics such as the clinical and public 

health impact of Severe Combined 

Immunodeficiency (SCID), carrier status 

in the context of newborn screening, 

and a review of long term follow up in 

newborn screening; and (4) updates 

from the Laboratory Standards and 

Procedures workgroup, Follow-up and 

Treatment workgroup, and Education 

and Training workgroup. The 

Committee will not be voting on a 

proposed addition of a condition to the 

RUSP. Agenda items are subject to 

change. The final meeting agenda will 

be available 2 days prior to the meeting 

on the Committee’s Web site: http://

www.hrsa.gov/advisorycommittees/ 

mchbadvisory/heritabledisorders. 

Members of the public will have the 

opportunity to provide comments. All 

comments are part of the official 

Committee record. To submit written 

comments or request time for an oral 

comment at the meeting, please register 

online by 11:59 p.m. Eastern Time on 

November 2, 2017, at http://

www.achdncmeetings.org/. To ensure 

all individuals who have registered and 

requested time for oral comments are 

accommodated, the allocated time for 

comments may be limited. Individuals 

associated with groups or who plan to 

provide comments on similar topics 

may be asked to combine their 

comments and present them through a 

single representative. No audiovisual 

presentations are permitted. Written 

comments should identify the 

individual’s name, address, email, 

telephone number, professional or 

organization affiliation, background or 

area of expertise (i.e., parent, family 

member, researcher, clinician, public 

health, etc.) and the topic/subject 

matter. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify Ann Ferrero using the address 

and phone number above at least 10 

days prior to the meeting. 

Amy McNulty, 

Acting Director, Division of the Executive 

Secretariat. 

[FR Doc. 2017–22313 Filed 10–13–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Planning Grant (R34) and Implementation 

Cooperative Agreement (U01). 

Date: November 6–9, 2017. 

Time: 9:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892, 

(Telephone Conference Call). 

Contact Person: Geetanjali Bansal, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

Room 3G49, National Institutes of Health/ 

NIAID, 5601 Fishers Lane, MSC 9834, 

Bethesda, MD 20892–9834, (240) 669–5073, 

geetanjali.bansal@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 10, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22259 Filed 10–13–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Translational Studies on Adducts For Cancer 

Risk Identification and Prevention. 

Date: November 8, 2017. 

Time: 1:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W108, Rockville, MD 20850, (Telephone 

Conference Call). 


ethrower on DSK3G9T082PROD with NOTICES
Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices 48105 

Contact Person: Clifford W. Schweinfest, 

Ph.D., Scientific Review Officer, Special 

Review Branch, Division of Extramural 

Activities, National Cancer Institute, NIH, 

9609 Medical Center Drive, Room 7W108, 

Bethesda, MD 20892–9750, 240–276–6343, 

schweinfestcw@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: October 10, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22246 Filed 10–13–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Medications Development. 

Date: November 1, 2017. 

Time: 8:00 a.m. 5:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: Hilton Garden Inn Bethesda, 7301 

Waverly Street, Bethesda, MD 20814. 

Contact Person: Ivan K. Navarro, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4242, MSC 9550, Bethesda, 

MD 20892, 301–827–5833, ivan.navarro@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos.: 93.279, Drug Abuse and 

Addiction Research Programs, National 

Institutes of Health, HHS) 

Dated: October 10, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22247 Filed 10–13–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute Amended; 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the National Cancer 

Institute Special Emphasis Panel, 

November 2, 2017, 9:00 a.m. to 

November 2, 2017, 7:00 p.m., National 

Cancer Institute Shady Grove, 9609 

Medical Center Drive, Rockville, MD 

20850 which was published in the 

Federal Register on September 22, 2017, 

82 FR 44429. 

This meeting notice is amended to 

change the meeting date from November 

2, 2017 to December 7, 2017. The 

meeting is closed to the public. 

Dated: October 10, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22245 Filed 10–13–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; PAR–16– 

443: Drug Abuse Dissertation Research. 

Date: November 1, 2017. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Robert Freund, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5216, 

MSC 7852, Bethesda, MD 20892, 301–435– 

1050, freundr@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Nursing and Related Clinical 

Sciences. 

Date: November 6, 2017. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Xin Yuan, MD, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3141, 

Bethesda, MD 20892, 301–827–7245, 

yuanx4@csr.nih.gov. 

Name of Committee: AIDS and Related 

Research Integrated Review Group; AIDS 

Clinical Studies and Epidemiology Study 

Section. 

Date: November 7–8, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Melrose Hotel, 2430 Pennsylvania 

Ave. NW., Washington, DC 20037. 

Contact Person: Dimitrios Nikolaos 

Vatakis, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Room 3190, Bethesda, MD 20892, 301–827– 

7480, dimitrios.vatakis@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Fellowship: 

AIDS and AIDS-related Applications. 

Date: November 7, 2017. 

Time: 8:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Jingsheng Tuo, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3196, 

Bethesda, MD 20892, 301–451–5953, tuoj@

csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Epidemiology of Environmental 

Exposures, Diet, Biomarkers, and Genetics in 

Chronic Disease. 

Date: November 7, 2017. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20814, 

(Telephone Conference Call). 

Contact Person: George Vogler, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3140, 

MSC 7770, Bethesda, MD 20892, (301) 237– 

2693, voglergp@csr.nih.gov. 


ethrower on DSK3G9T082PROD with NOTICES